Patricia Roxburgh

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity

790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2